What Braingaze does

Braingaze is a digital cognitive health company that develops eye-tracking AI solutions for the diagnosis and therapeutic management of neurodevelopmental and neurocognitive conditions, primarily ADHD. Founded in 2013 as a spin-off from the University of Barcelona and now headquartered in London with substantial operations in Mataro (Barcelona), the company's core technology is its patented Cognitive Vergence method, which uses involuntary eye-movement biomarkers linked to brainstem activity as an objective, quantifiable diagnostic input. This is operationalized through two products: BGaze Clinic, a clinician-facing diagnostic platform that combines a 12-minute eye-tracking test with multi-parameter explainable AI to deliver up to 92% diagnostic accuracy, automated DSM-5/ICD-11 scoring, and questionnaire delivery to up to six informants; and BGaze Focus, a suite of gaze-controlled therapeutic games delivered on iOS and Android that targets ADHD, autism, and dyslexia symptoms without requiring specialized hardware.

The company is CE Marked and compliant with NHS DSP Toolkit, GDPR, and HIPAA, and has accumulated 6,000+ supported patient diagnoses supported by 20+ peer-reviewed clinical studies with research partners including King's College London, Sant Joan de Deu, Vall d'Hebron, Syracuse University, and Radboud University. Braingaze monetizes via annual subscription licensing to clinicians and clinics for BGaze Clinic and via clinic-channel distribution of BGaze Focus to patients, with sales-led go-to-market targeting psychiatrists, psychologists, neurologists, and pediatricians in private clinics and NHS trusts. In March 2024, Braingaze closed a €1.5 million seed round led by RYSE Asset Management with Orbit Startups and Artesian, with the company subsequently relocating its HQ to London and joining the DTx Consortium's partnership with Vodafone Business to scale distribution in Spain. The company operates with 1-10 employees including co-founders Laszlo Bax (CEO) and Prof. Hans Supèr (CTO), plus a Lead AI Engineer, regulatory lead, and clinical research officer.

Name

Braingaze

Legal name

Braingaze Ltd

Website

https://braingaze.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Braingaze develops AI-powered eye-tracking diagnostics and gaze-controlled therapeutic games for ADHD and neurodevelopmental conditions, selling to clinicians, NHS trusts, and hospitals via subscription licensing.

Ownership category

akta.pro rank

Product category

Neurodevelopmental Digital Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Eye-tracking diagnostics
• ADHD diagnostic platform
• Cognitive biomarker analysis
• Gaze-controlled therapy
• Digital therapeutics ADHD

Headquarters

HQ city

Mataró

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. BGaze Clinic Diagnostic Platform: Subscription or per-use licensing model for clinical diagnostic services using the BGaze Clinic platform. Clinicians pay for access to the eye-tracking diagnostic tool and reporting features.
2. BGaze Focus Therapeutic App: Clinician-procured access to gaze-controlled gaming therapy. Patients access the app through clinician-provided access codes. Revenue generated through clinic licensing arrangements.
3. Digital Cognitive Health Solutions: Diagnostic and therapeutic solutions for cognitive disorders, including mobile-based solutions launched with investment funding.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Braingaze develops eye-tracking AI solutions for the diagnosis and therapy of neurodevelopmental conditions, primarily ADHD. Its BGaze Clinic product is a diagnostic support platform that uses the patented Cognitive Vergence eye-movement biomarker with xAI analysis to deliver 92%+ accuracy in a 12-minute test, including automated DSM-5/ICD-11 scoring. Its BGaze Focus product is a mobile suite of gaze-controlled therapeutic games designed to improve attention and reduce symptoms of ADHD, autism, and dyslexia, distributed through clinicians and partner clinics.

Product overview

Braingaze offers a dual-product portfolio centered on eye-tracking and AI technology for neurodevelopmental condition management. The core offering consists of BGaze Clinic, a diagnostic support system using patented Cognitive Vergence eye-movement biomarker analysis with xAI to achieve 92% diagnostic accuracy for ADHD in 12 minutes; and BGaze Focus, a mobile-based therapeutic gaming application that uses gaze-controlled games to improve attention and focus symptoms. Both products leverage the same underlying Cognitive Vergence technology and can be used at different stages of the diagnosis and treatment journey. BGaze Clinic targets clinicians for diagnostic support, while BGaze Focus targets patients and clinicians for ongoing therapeutic intervention.

Differentiator

Problem solved

Functional benefit

Brands

• BGaze Clinic: Diagnostic support system leveraging advanced eye-tracking hardware to capture involuntary eye movement biomarkers for ADHD diagnosis with up to 92% accuracy
• BGaze Focus

Products and services

• BGaze Clinic BGaze Clinic is a diagnostic support system for clinicians that uses a 12-minute eye-tracking test combined with AI-powered analysis to detect involuntary eye movement biomarkers (Cognitive Vergence) and deliver up to 92% diagnostic accuracy for ADHD. The platform automates questionnaire delivery to up to 6 informants, applies DSM-5 and ICD-11 scoring, and produces comprehensive reports that streamline clinical workflows. It is CE Marked, compliant with NHS DSP Toolkit cybersecurity standards, GDPR, and HIPAA.
• BGaze Focus BGaze Focus is a suite of gaze-controlled therapeutic games for mobile devices that improves attention and focus in individuals with ADHD, Autism, and Dyslexia. Players control game mechanics using only their eyes on standard iOS and Android devices without specialized hardware. It is distributed through clinicians and partner clinics (e.g., CAN Clinic and Spectrum Clinic), with access provided via clinician credentials. The product has demonstrated clinical effect sizes of 0.7-1.0, comparable to non-stimulant ADHD medication or CBT.

Quantifiable outcome

• 92%+ diagnostic accuracy with fewer than 6% false positives and negatives
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and major.

• DTx ConsortiumcoreStrategic or Co-development PartnerDTx Consortium collaborated with Vodafone Business to promote the use of digital therapies in Spain. This agreement aimed to promote access to innovative digital treatments to improve population health using Vodafone's infrastructure and technology for nationwide implementation.
• Vodafone BusinesscoreStrategic or Co-development PartnerPartnered with DTx Consortium to drive adoption of digital therapies in Spain. Provided infrastructure and technology to support implementation and distribution of digital therapies nationwide.
• King's College LondonmajorStrategic or Co-development PartnerResearch partner in neurodevelopmental diagnostics validation. Collaborates on clinical validation of eye-tracking diagnostic technology.
• Sant Joan de Deu HospitalmajorStrategic or Co-development PartnerClinical research partner with Dr. José Alda serving as ADHD Lead. Collaborates on clinical trials and validation studies for ADHD diagnosis.
• CAN CliniccoreChannel Partner/ Reseller/ DistributorPartner clinic offering BGaze Focus therapeutic games to patients. One of the initial wave of partner clinics when BGaze Focus launched.
• Spectrum CliniccoreChannel Partner/ Reseller/ DistributorPartner clinic offering BGaze Focus therapeutic games to patients. One of the initial wave of partner clinics when BGaze Focus launched.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• NeuroNation: Consumer and clinical brain-training app targeting attention, memory, and ADHD-adjacent cognitive skills. Overlaps with BGaze Focus in the gaze/attention training category, with stronger direct-to-consumer distribution.
• Limbic: UK-based AI platform powering digital mental health assessment and self-referral for NHS talking therapies. Comparable as a UK digital mental health entrant pursuing NHS contracts, though its focus is on access/triage rather than biomarker diagnostics.
• Healios: UK digital mental health provider delivering evidence-based family interventions including ADHD-focused programs via NHS. Comparable as a UK-based digital therapeutic delivery model targeting ADHD/autism populations.
• Big Health: Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), operating in the prescription DTx category. Comparable as a clinically validated, evidence-led DTx business model targeting mental health indications.

Broad incumbents

• Pearson Clinical: Major provider of standardized cognitive and neuropsychological assessments (e.g., WISC, WAIS) widely used by clinicians. Competes indirectly with BGaze Clinic in the cognitive assessment workflow.
• PAR (Psychological Assessment Resources): Established publisher of psychological assessment instruments including the Conners rating scales, the de facto standard questionnaire-based ADHD assessments. Represents the incumbent paradigm Braingaze is positioning to disrupt with objective biomarker data.

Direct peers

• Qbtech: Swedish company that produces QbTest, an FDA-cleared / CE-marked objective ADHD diagnostic combining Continuous Performance Test (CPT) and motion tracking. It is the closest direct competitor to Braingaze's BGaze Clinic in objective ADHD measurement.
• Cogstate: Provides computerized cognitive testing batteries (e.g., CANTAB) used by clinicians and in clinical trials for objective cognitive assessment. Overlaps with Braingaze's positioning as an objective, digital, biomarker-driven cognitive assessment.
• Creyos: Online cognitive assessment platform (formerly Cambridge Brain Sciences) offering brief, validated brain-health tests for clinicians and researchers. Competes with BGaze Clinic in the digital cognitive-assessment category for ADHD and related conditions.
• Akili Interactive (now Virtual Therapeutics): Digital therapeutic company behind EndeavorRx, an FDA-authorized prescription video game treatment for pediatric ADHD. Braingaze's BGaze Focus competes in the same gaze/attention-based DTx category for ADHD symptom improvement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/braingaze

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Braingaze